Seeking Alpha

Insmed Incorporated (INSM +2%) gains after the FDA grants orphan drug designation to Arikace, an...

Insmed Incorporated (INSM +2%) gains after the FDA grants orphan drug designation to Arikace, an inhaler for treating infections caused by non-tuberculous mycobacteria. The company notes that there's currently no FDA-approved treatment for this particular NTM lung infection.
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs